Utah Group Launches Campaign To Legalize Magic Mushrooms For Therapeutic & Academic Purposes
[ad_1] The new non-profit, Utah Mushroom Therapy, recently launched a campaign to support the legalization of magic mushrooms, also known as psilocybin. The move follows last February’s creation of a government task force to study…
atai Life Sciences’ Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges – ATAI Life Sciences (NASDAQ:ATAI)
[ad_1] Clinical-stage psychedelics biotech atai Life Sciences ATAI shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression…
Treating Binge Eating Disorder With Magic Mushrooms: Phase 2 Clinical Trial Gets Thumbs Up – Tryp Therapeutics (OTC:TRYPF)
[ad_1] Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. TRYPF shared the interim results for the first five patients dosed in its Phase 2 STOP (Study of the Treatment of Overeating utilizing…
Is Psychedelic Treatment Around The Corner? MDMA For PTSD Checks Positive In MAPS’ 2nd Phase 3 Trial
[ad_1] MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therapy for…
New Sublingual Psychedelic Drug Candidate Created For Depression And Anxiety In Alzheimer’s – Biomind Labs (OTC:BMNDF)
[ad_1] Psychedelics R&D biotech Biomind Labs Inc. BMNDF has completed the development of a novel sublingual formulation and the first production batch for testing in its Phase 2 trial on…